Intravenous administration of galanin into fasted conscious dogs produced a dose-dependent hyperglycemia accompanied by decreases in plasma insulin levels, but with no elevation of plasma glucagon levels. Galanin infusions produced greater parenteral glucose-induced rises in plasma glucose levels along with markedly blunted insulin responses compared with glucose and insulin responses to control glucose infusions. Immediately after cessation of the galanin infusions, elevation of plasma insulin levels occurred in the basal state and after parenteral glucose loading. These results suggest that galanin's hyperglycemic activity is predominantly mediated by a reversible inhibition of insulin secretion. DIABETES 1985; 34:192-96.
1
Initial studies demonstrated galanin's ability to contract smooth muscle preparations from the rat and to cause a mild but sustained hyperglycemia in the conscious dog. 1 The studies reported here were designed to investigate the mechanism of galanin-induced hyperglycemia and to determine the effect of galanin on parenteral glucose-induced insulin release.
MATERIAL AND METHODS
Experiments were performed on surgically intact conscious dogs. After an overnight fast, intravenous catheters were placed in a hindlimb for blood sampling and a forelimb for administration of peptides or control saline infusions. Porcine intestinal galanin, prepared as described, 1 was dissolved in saline just before administration. In dose-response experiments, four dogs had 60-min infusions of galanin at doses of 0 (saline control), 0.5, 1.0, and 2.0 jxg • k g 1 • h~1, and two dogs had 60-min infusions at 4.0 |xg • kg~1 • h " 1 . Blood samples were obtained at -1 5 , 0 (just before infusion initiation), 5, 10, 20, 30, 40, 50, 60, 70, and 90 min after initiation of the infusion. The effect of galanin infusion on glucoseinduced elevation of plasma insulin levels was investigated in four overnight-fasted dogs. On day 1 the dogs received a 1-h control 1 g • kg" 1 • h" 1 glucose infusion and on a separate day subjected to an identical glucose infusion but with the addition of a simultaneous 60-min i.v. infusion of galanin at 2 |xg • kg" 1 • h" 1 . Blood samples were obtained at the same time intervals as in the dose-response experiments. In separate experiments, four dogs were infused with [3-3 H]glucose (New England Nuclear, Boston, Massachusetts) for 150 min before and during a 2-h infusion of galanin at 2.0 |xg • kg" 1 • h"\ and the effects on glucose turnover determined as previously described. 5 In any experiment, less than 10% of the dog's blood volume was taken.
Blood samples were collected on ice into lightly heparinized tubes with the addition of 800 KIU aprotinin (Novo Research Institute, Copenhagen, Denmark) per ml of blood, centrifuged at 4°C, and the plasma stored at -20°C until a) Galanin 1 5 10 15 Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-H1s-Ala-20 25 Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-leu-Ala-NrU radioimmunoassay. Radioimmunoassay for plasma insulin, glucagon (30 K antiserum of Dr. Roger Unger), and gastrin levels were performed at the University of Western Ontario as previously described. 6 Plasma levels of gastric inhibitory polypeptide, pancreatic polypeptide, and pancreatic glucagon (RCS-5 antiserum) were performed at the University of Toronto as described. 7 A small amount of each blood sample was collected on ice into sodium fluoride-heparin tubes for determination of plasma glucose using a glucoseoxidase technique (Beckman glucose analyzer II, Beckman Instruments, Inc., Fullerton, California).
All values are expressed as mean ± standard error of the mean (SEM) unless otherwise stated. In the dose-response study, responses of plasma glucose and insulin are expressed as changes from basal values (0-min sample). In all other cases, results are expressed as absolute values. Student's f-test for paired data was used to examine the significance of the differences between elevated and basal hormone and glucose levels, and the f-test for unpaired means was applied to test significant differences between experimental versus control values of hormone or glucose levels. A value of P < 0.05 was considered as a significant difference.
RESULTS
No evidence of distress was seen during infusions of galanin at any dose. (Table 1) , but plasma levels of pancreatic polypeptide (Table 1 ) and gastrin (data not shown) tended to decrease during the galanin infusion. Table 2 lists the plasma glucose responses and glucose turnover data for 2-h galanin infusions at 2 |xg • kg 1 • h 1 in four dogs. Immediately after initiation of the infusion, a de- crease in the fractional disappearance rate of glucose (k) occurred that was sustained until close to the termination of the infusion. A small transient rise of the rate of appearance of glucose (Ra) occurred on initiation of the infusion but fell below basal values by mid-infusion, with a further decline occurring on cessation of the infusion. Figure 3a shows the plasma glucose responses in four dogs during glucose infusions with and without simultaneous 2 |xg • kg 1 • h~1 galanin infusions. During the galanin infusions, plasma glucose levels attained were significantly higher compared with control glucose infusion values. Despite the much higher glucose levels attained during the galanin infusions, plasma insulin responses were remarkably blunted ( Figure 3b control glucose infusions. At termination of the galanin infusion, an immediate elevation of insulin levels was seen.
DISCUSSION
These studies demonstrate that in the fasted state galanin produces a dose-dependent hyperglycemia in conscious dogs with a concomitant fall of plasma insulin levels. The hyperglycemia was sustained throughout the galanin infusion, and plasma insulin levels remained below basal values but tended to rise toward basal levels before the end of the infusion. The glucose turnover studies demonstrated a decrease in the fractional disappearance rate of glucose (k), a finding consistent with the fall in plasma insulin levels. Two possible mechanisms may account for the transient rise in glucose production (Ra) during the galanin infusions. First, if galanin caused the secretion of catecholamines, an expected result would be inhibition of insulin release and glycogenolysis. Despite sustained glucose elevations, Ra fell below basal values by mid-infusion, and there was no elevation of plasma glucagon or gastrin levels, as may be seen with increased catecholamine secretion. 89 Nonetheless, investigations into the possibility that galanin may stimulate catecholamine secretion are indicated; such bioactivity would be of interest for further study. Second, previous studies have demonstrated increased sensitivity of the liver to sustained glucagon levels during suppression of plasma insulin levels.
1011 During the galanin infusions, the peak of Ra occurs at the nadir of plasma insulin levels, and the fall of Ra occurs as the plasma insulin levels tend to rise. These observations would be consistent with galanin having a noncatecholamine-mediated action to lower plasma insulin levels, thereby allowing an increased sensitivity of the liver to the sustained glucagon levels seen during galanin infusions.
During the galanin infusions in the fasted state, no change was seen in plasma levels of GIP and glucagon, two hormones capable of affecting plasma glucose and insulin levels. However, investigations on the effect of galanin on the plasma responses of GIP and glucagon during stimulation are necessary before it can be concluded that galanin does not affect their release. Similarly, further investigation into the effect of galanin on the secretion of pancreatic polypeptide and gastrin are indicated since their plasma levels tended to decrease during galanin infusions in the basal state.
Systemic somatostatin infusions in man and dog produce greater falls in plasma levels of glucagon compared with those of insulin, and are associated with an initial decrease in plasma glucose levels. 1011 In contrast, galanin infusions produced an immediate hyperglycemia and fall in plasma insulin levels but did not significantly change plasma glucagon levels. Therefore, it seems unlikely that galanin's effect is mediated via release of somatostatin into the peripheral circulation. However, it has been postulated that biologic actions of somatostatin may be exerted not only via hormonal mechanisms but also at a strictly local level via paracrine mechanisms. Thus, the present study does not exclude the possibility that the observed effects of galanin may be due to the stimulation of such somatostatin-mediated paracrine actions within the islet. This study also demonstrates that i.v. galanin produces a blunting of the plasma insulin responses to parenteral glucose, probably accounting for the higher glucose levels seen during the galanin infusions. In both the basal state and during parenteral glucose stimulation, on termination of the galanin infusion, an immediate elevation of plasma insulin levels was seen. These findings suggest that during galanin infusions the beta cell is inhibited from responding normally to elevated plasma glucose levels but that this inhibition is readily reversible.
In summary, galanin infusion in the dog appears to inhibit insulin secretion in the basal state and during parenteral glucose administration. The mechanism of action of this in-
GALANIN INHIBITS INSULIN SECRETION AND INDUCES HYPERGLYCEMIA IN DOGS
hibition is unknown. Galanin was isolated from the porcine upper small intestine and although its tissue distribution is not fully known, there is preliminary evidence that it is present in the pancreas. 12 The demonstration that this newly identified Gl peptide can alter insulin secretion suggests that it may have a regulatory function in the secretion of insulin and consequently may be of physiologic and/or pathophysiologic importance.
